Michael B Atkins
Georgetown University · Hoosier Cancer Research Network · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael B Atkins as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05928806 · Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialMichael B. Atkins, MD · suspended · Advanced Renal Cell Carcinoma · principal investigator
- Ph2NCT03117309 · Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaMichael B. Atkins, MD · completed · Advanced Renal Cell Carcinoma · study chair
- Ph3NCT02224781 · Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaNational Cancer Institute (NCI) · active not recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma · principal investigator
- Ph2NCT01813214 · The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With MelanomaGeorgetown University · terminated · Melanoma · principal investigator
- Ph2NCT01495988 · Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaMelanoma Research Foundation Breakthrough Consortium · terminated · Melanoma, Metastatic Melanoma · principal investigator
- Ph2NCT01435369 · Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic MelanomaMedivation, Inc. · completed · Melanoma, Malignant Melanoma · principal investigator
- Ph1NCT00003330 · Interleukin-12 in Treating Patients With Advanced CancerNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph2NCT00077129 · Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell CancerEastern Cooperative Oncology Group · completed · Kidney Cancer · study chair
- Ph3NCT00006237 · S0008: Chemotherapy Plus Biological Therapy in Treating Patients With MelanomaSWOG Cancer Research Network · completed · Melanoma (Skin) · study chair
- Ph3NCT00003027 · Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic MelanomaEastern Cooperative Oncology Group · completed · Melanoma (Skin) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- (PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitorsR01CA231291 · NCI · GEORGETOWN UNIVERSITY · fiscal years 2018 to 2022 · $522,708 awarded in 2022Same name and institution; not confirmed by an ID
- Career Development ProgramP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2003 to 2013 · $68,398 awarded in 2013Same name and institution; not confirmed by an ID
- Eastern Cooperative Oncology GroupU10CA080775 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2002 to 2011 · $95,412 awarded in 2011Same name and institution; not confirmed by an ID
- Biologic therapy of Melanoma and Renal Cell CancerK24CA093479 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 2002 to 2006 · $115,395 awarded in 2006Same name and institution; not confirmed by an ID
- Phase 1 Trial of twice weekly IV IL-12 plus low-dose subcutaneous IL-2M01RR001032 · NCRR · BETH ISRAEL DEACONESS MEDICAL CENTER · fiscal years 1998 to 2004 · $6,214 awarded in 2004Same name and institution; not confirmed by an ID
- TRIAL OF CONCURRENT BIOCHEMOTHERAPY W/ CISPLATIN, DACARBAZINE, VINPLASTINE, IL2M01RR000054 · NCRR · TUFTS MEDICAL CENTER · fiscal years 1995 to 1999 · $47,827 awarded in 1999Same name and institution; not confirmed by an ID
- PHASE I/II--CLINICAL EVALUATION OF BIOLOGICAL RESPONSEN01CM027784 · NCI · TUFTS MEDICAL CENTER · fiscal years 1992 to 1994 · $38,845 awarded in 1994Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT02224781
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013Named on NCT00006237
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:06 UTC. The ranking covers the 200 most relevant of 142 PubMed records, and a shared surname and initials can bring in a namesake. All 142 on PubMed
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med · 201210,484 citationsRCR 282.6
- 2,795 citationsRCR 104.7
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med · 20192,011 citationsRCR 74.6
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol · 20141,889 citationsRCR 53.5
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med · 20171,847 citationsRCR 59.7
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.N Engl J Med · 20181,088 citationsRCR 35.8
- 1,038 citationsRCR 31.3
- 828 citationsRCR 15.6
- 826 citationsRCR 28.5
- Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.N Engl J Med · 2023784 citationsRCR 65.0